Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416995 | 0.91 | ALDH1A1 (0.44) | ATMALDH1A1HTR1ASLC6A4SIGMAR1 | |
| SCHEMBL6415988 | 0.90 | ATM (0.43) | ATMHTR1ASLC6A4SIGMAR1CCR3 | |
| SCHEMBL6417597 | 0.88 | CCR3 (0.39) | SIGMAR1CCR3 | |
| SCHEMBL6413847 | 0.87 | HTR1A (0.60) | HTR1ASLC6A4SIGMAR1CCR3MEN1 | |
| SCHEMBL6416520 | 0.87 | P2RX7 (0.41) | ATMALDH1A1HTR1ASLC6A4SIGMAR1 | |
| SCHEMBL6410904 | 0.87 | ATM (0.43) | ATMALDH1A1HTR1ASLC6A4SIGMAR1 | |
| SCHEMBL6411343 | 0.86 | HTR1A (0.49) | ATMALDH1A1HTR1ASLC6A4SIGMAR1 | |
| SCHEMBL6414678 | 0.86 | CCR3 (0.37) | HTR1ASLC6A4CCR3 | |
| SCHEMBL6412195 | 0.85 | HTR1A (0.49) | ATMALDH1A1HTR1ASLC6A4SIGMAR1 | |
| SCHEMBL6411180 | 0.82 | HTR1A (0.43) | ATMALDH1A1HTR1ASLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | ATM 4128/4885ALDH1A1 828/4885HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.